CLASSIC HODGKIN LYMPHOMA
Clinical trials for CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo aims to outsmart resistant hodgkin lymphoma
Disease control TerminatedThis phase 2 study tests whether combining magrolimab and pembrolizumab can shrink or eliminate tumors in people with classic Hodgkin lymphoma that has come back or not responded to at least two prior treatments. Magrolimab targets a 'don't eat me' signal on cancer cells, while p…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Ranjana Advani • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
Experimental lymphoma drug combo shows promise in early trial
Disease control TerminatedThis study tested a new drug called SAR444245, alone or with pembrolizumab, in 14 people aged 12 and older with B cell lymphoma that came back or didn't respond to treatment. The goal was to see if the drug could shrink tumors. The study was terminated early, so results are limit…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Lymphoma drug combo trial halted early – what we know
Disease control TerminatedThis early-stage trial tested two drugs, isatuximab and cemiplimab, together in 58 people with relapsed or refractory lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so while some safety and response data were col…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC